Trial Profile
A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Aldesleukin (Primary) ; Aldesleukin (Primary) ; Antiretrovirals
- Indications HIV-1 infections
- Focus Therapeutic Use
- 10 May 2012 Status of rollover trial is completed as reported by ClinicalTrials.gov.(NCT00000923).
- 10 May 2012 Status of rollover trial is completed as reported by ClinicalTrials.gov.(NCT00000923).
- 10 May 2012 Status of rollover trial is completed as reported by ClinicalTrials.gov.(NCT00000923).